A kind of polypeptide of Rana spinosa for inhibiting xanthine oxidase activity and its preparation method and application
Through the preparation and application of the polypeptide of the spiny-chest frog, the problem of major side effects of existing hyperuricemia treatment drugs has been solved, safe and effective uric acid reduction effect has been achieved, and the application value of spiny-chest frog processed products has been broadened.
Patent Information
- Application Number
- CN202211550832.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-05
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2042-12-05
AI Technical Summary
Existing hyperuricemia treatment drugs have serious side effects and lack effective and safe natural uric acid-lowering substances, resulting in limited therapeutic effects.
A polypeptide of the thyroid carp is developed to inhibit xanthine oxidase activity. The polypeptide is prepared by multi-step enzymatic lysis and ultrafiltration chromatography of the thyroid carp skin, and the inhibitory effect of xanthine oxidase is used to reduce uric acid levels.
This spiny-chest frog polypeptide has a powerful and safe inhibitory effect of xanthine oxidase, effectively reduces uric acid levels, broadens the added value of frog skin, and reduces drug side effects.
Smart Images

Figure CN116041429B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a Rana spinosa polypeptide capable of inhibiting xanthine oxidase activity, and a preparation method and application thereof. Background Art
[0002] The spiny-chested frog is also known as the "living ginseng in mountain springs" because of its dual value of being both edible and medicinal. At present, the main marketing methods for spiny-chested frogs are catering sales and live retail. Most of the frog meat sold on the market is peeled fresh frog meat, and processed products are relatively rare. The industrial chain is simple and the processed products are in a single form. The processing of spiny-chested frogs will produce many by-products such as frog skin, bones, and internal organs. The rational use of by-product resources such as frog skin has a positive impact on the diversification and high-value development of spiny-chested frogs.
[0003] The prevalence of hyperuricemia among adults in my country has reached 24.4%. In addition to the rapid increase in prevalence, the average age of the affected population has also gradually decreased. Hyperuricemia is characterized by an increase in serum uric acid levels. The accumulation of uric acid crystals in the joints will further induce gouty arthritis, kidney stones and other kidney diseases. The main cause of the increase in uric acid levels is xanthine oxidase (XOD), which catalyzes xanthine and hypoxanthine to form uric acid. At present, probenecid, benzbromarone (drugs that promote uric acid excretion), purine, rasburicase (drugs that decompose uric acid) and allopurinol (drugs that inhibit uric acid synthesis) are commonly used in the treatment of hyperuricemia. Among them, some drugs can cause more serious side effects: liver and kidney damage, hypersensitivity reactions, diarrhea, stomach pain, rash, etc. Therefore, there is an urgent need to screen natural uric acid-lowering substances with good effects and few side effects to relieve hyperuricemia. Summary of the invention
[0004] To solve the above problems, the embodiments of the present invention provide, in a first aspect, a Rana spinosa polypeptide that inhibits xanthine oxidase activity, the amino acid sequence of which is shown in SEQ ID NO:1.
[0005] According to an embodiment of the present invention, a Rana spinosa polypeptide for inhibiting xanthine oxidase activity has a molecular weight of 750.3701 Da. The polypeptide has the advantages of strong xanthine oxidase inhibition and safety without toxic side effects, and can be used as a uric acid-lowering drug to broaden the added value of frog skin.
[0006] In a second aspect, an embodiment of the present invention provides a method for preparing the above-mentioned Rana spinosa polypeptide that inhibits xanthine oxidase activity, characterized in that it comprises the following steps:
[0007] (1) The frog skin of Rana spinosa was homogenized with distilled water according to the material-liquid ratio of 1 g:15-25 mL, the pH was adjusted to 6.5-7.5, 4%-6% papain was added according to the weight of the frog skin, the enzymatic hydrolysis temperature was adjusted to 40-50°C, the enzymatic hydrolysis was carried out for 4-6 hours, and the enzyme was inactivated with boiling water for 10 minutes;
[0008] (2) adjusting the pH of the enzymatic solution after the enzyme inactivation in step (1) to 1.0-3.0, adding 4%-6% of acidic protease according to the weight of frog skin, adjusting the enzymatic hydrolysis temperature to 45-55° C., and performing enzymatic hydrolysis for 4-6 hours and then inactivating the enzyme in boiling water for 10 minutes;
[0009] (3) Centrifuging the enzymatic hydrolyzate after the enzyme inactivation in step (2), taking the supernatant, and subjecting it to ultrafiltration and chromatography to obtain a Rana spinosa polypeptide that inhibits xanthine oxidase activity.
[0010] According to an embodiment of the present invention, the method performs step-by-step enzymatic hydrolysis on frog skin, and then performs ultrafiltration and chromatography to obtain a Rana spinosa polypeptide capable of inhibiting the activity of xanthine oxidase.
[0011] Optionally, in step (1), the enzymatic activity of papain is ≥200 U / mg.
[0012] Optionally, in step (2), the enzyme activity of the acidic protease is ≥200 U / mg.
[0013] Optionally, in step (3), ultrafiltration is performed using an ultrafiltration tube with a molecular weight cutoff of 3 kD to collect enzymatic hydrolysis products with a molecular weight less than 3 kD.
[0014] Optionally, in step (3), the chromatography is to use Sephadex G-15 gel chromatography column to perform column chromatography on the ultrafiltered enzymatic hydrolysate: the loading concentration is 20-40 mg / mL, the loading volume is 2-4 mL, the flow rate is 980 μL / min, one tube is collected every 10 minutes, and the absorbance curve is detected at 220 nm and drawn.
[0015] Optionally, the components after chromatography are purified by reverse-phase high-performance liquid chromatography, and the reverse-phase high-performance liquid chromatography conditions are: injection volume 10-20 μL; using a C18 reverse chromatographic column, the column temperature is 25-30°C, the mobile phase: A is water containing 0.1% trifluoroacetic acid, B is acetonitrile, gradient elution: 0-40min, acetonitrile concentration from 0 to 50%, elution rate 1.0mL / min; ultraviolet detection wavelength 280nm.
[0016] According to an embodiment of the present invention, the present invention further proposes the use of the above-mentioned Rana spinosa polypeptide in the preparation of uric acid-lowering drugs, so as to achieve high value-added comprehensive utilization of Rana spinosa.
[0017] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 Column chromatography elution diagram of the enzymatic ultrafiltration product according to an embodiment of the present invention;
[0019] Figure 2 is a reverse HPLC chromatogram of a Rana spinosa polypeptide according to an embodiment of the present invention;
[0020] Figure 3 is a mass spectrum of a Rana spinosa polypeptide according to an embodiment of the present invention;
[0021] Figure 4 The conformation of the Rana spinosa polypeptide in the XOD pocket, the binding mode in the XOD active site, and the interaction plane diagram according to the embodiments of the present invention;
[0022] Figure 5 is the xanthine oxidase inhibitory activity of the ultrafiltration fraction according to the example of the present invention, and ad indicates that the difference between the groups is extremely significant (P<0.05);
[0023] Figure 6 The cytotoxicity of the Rana spinosa polypeptide according to the examples of the present invention to LO2 cells. DETAILED DESCRIPTION
[0024] The technical solution of the present invention is described below through specific examples. It should be understood that the one or more method steps mentioned in the present invention do not exclude the existence of other method steps before and after the combination step or the insertion of other method steps between these explicitly mentioned steps; it should also be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention. Moreover, unless otherwise specified, the numbering of each method step is only a convenient tool for identifying each method step, and is not intended to limit the order of arrangement of each method step or to limit the scope of the present invention. The change or adjustment of the relative relationship thereof shall also be regarded as the scope of the present invention without substantially changing the technical content.
[0025] In order to better understand the above technical scheme, the exemplary embodiments of the present invention are described in more detail below. Although exemplary embodiments of the present invention are shown, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present invention and to enable the scope of the present invention to be fully communicated to those skilled in the art.
[0026] The test materials used in the present invention are all common commercial products and can be purchased in the market.
[0027] The present invention is described below with reference to specific embodiments. It should be noted that these embodiments are merely illustrative and do not limit the present invention in any way.
[0028] Example 1
[0029] (1) The skin of Rana spinosa was homogenized with distilled water at a solid-liquid ratio of 1 g:15 mL, and the pH was adjusted to 7.0. 4% papain (enzyme activity ≥ 200 U / mg) was added based on the weight of the skin. The enzymatic hydrolysis temperature was adjusted to 50°C. After enzymatic hydrolysis for 4 h, the enzyme was inactivated with boiling water for 10 min.
[0030] (2) The pH of the enzymatic solution after the enzyme inactivation in step (1) was adjusted to 2.0, 6% acid protease (enzyme activity ≥ 200 U / mg) was added based on the weight of frog skin, and the enzymatic hydrolysis temperature was adjusted to 45° C. After the enzymatic hydrolysis treatment for 4 h, the enzyme was inactivated in boiling water for 10 min.
[0031] (3) After the enzyme is inactivated in step (2), the enzymatic hydrolyzate is cooled to room temperature, centrifuged at 10,000 rpm for 10 min at 4°C, and the supernatant is collected after centrifugation.
[0032] (4) The supernatant of step (3) was separated and graded using ultrafiltration tubes with a molecular weight cutoff of 3 kD and 10 kD to obtain three components: QSPH-I (<3 kD), QSPH-II (3-10 kD), and QSPH-III (>10 kD).
[0033] (5) The QSPH-Ⅰ enzymatic hydrolysate after ultrafiltration in step (4) was purified by column chromatography using a Sephadex G-15 gel chromatography column (specification: Φ1.6×60 cm). The loading concentration was 40 mg / mL, the loading volume was 4 mL, the flow rate was 980 μL / min, one tube was collected every 10 min, and the absorbance curve was detected at 220 nm. The results are shown in the figure. Figure 1 As shown, fractions 1 to 4 were collected and freeze-dried, and then their xanthine oxidase inhibitory activities were detected. Among them, the fractions with the highest xanthine oxidase inhibitory activities in tubes 11 to 13 were gel chromatography hydrolysates.
[0034] (6) The gel chromatography hydrolysate was prepared into a 50 μg / mL solution with double distilled water, and purified by reverse phase high performance liquid chromatography. Based on the xanthine oxidase inhibitory activity, a polypeptide Gly-Ile-Pro-Gly-Phe-Gly-Gly-Phe with xanthine oxidase inhibitory activity was obtained; the reverse phase high performance liquid chromatography conditions were: injection volume 10 μL; C18 reverse phase chromatography column (Acclaim PepMap RSLC, 75 μm×25 cm C18-2 μm ); column temperature was 30°C; mobile phase: A was water containing 0.1% trifluoroacetic acid, B was acetonitrile; gradient elution: acetonitrile concentration was from 0 to 50% in 0-40min; elution rate was 1.0mL / min, and UV detection wavelength was 280nm. The reverse HPLC results are shown in the figure Figure 2 As shown, the single peak with a retention time of 12.358 min is the most active peptide.
[0035] Example 2
[0036] A C18 reverse phase column (Acclaim PepMap RSLC, 75 μm × 25 cm C18-2 μm ), the mobile phase was acetonitrile / water / formic acid = 5 / 95 / 0.1 (v / v), and the mobile phase A was reduced from 95% to 62% within 60 min. The mass spectrometer used the ThermoFisher Q Exactive system (Thermo Fisher, USA) combined with the nanospray Nano Flex ion source, the spray voltage was 1.9 kV, and the ion transfer tube heating temperature was 275 ° C. The mass spectrometer scanning mode was the information-dependent acquisition mode (Data Dependent Analysis, DDA), the primary mass spectrometer scanning range was 100-1500 m / z, the scanning resolution was 70000, and the maximum injection time was 100 ms. In each DDA cycle, up to 20 secondary spectra with charges of 1+ to 3+ were collected, and the maximum injection time of the secondary mass spectrometer ions was 50 ms. The collision cell energy (high energy collision induced dissociation, HCD) was set to 28 eV, applicable to all precursor ions, and the dynamic exclusion was set to 6 seconds.
[0037] Get as Figure 3 The mass spectrum shown selects the ion of the target peptide as the parent ion to collide with the inert gas to break the peptide bond in the peptide chain to form a series of ions. The N-terminal fragment ion series is marked as the b series, and the C-terminal fragment ion series is marked as the y series. By comprehensively analyzing these fragment ion series, it can be concluded that the amino acid sequence of the peptide is Gly-Ile-Pro-Gly-Phe-Gly-Gly-Phe.
[0038] Example 3
[0039] Based on molecular docking, the peptides identified by mass spectrometry were screened for biological activity using the software Autodock (version 4.2). The spatial structure of the peptide was drawn by ChemDraw 11.0 (Cambridge Soft Corporation, Cambridge, Massachusetts, USA). The peptide structure was saved in mol2 format using Open Babel GUI, and the peptide molecular structure was constructed using the Tripos force field energy minimization principle. The protonation state and hydrogen orientation were optimized in Autodock and saved as pdbqt files as ligand files. The Lamarkian genetic algorithm (LGA) was used for docking calculations, and energy range = 4.0, exhaustiveness = 9.0, and num modes = 30.0 were set.
[0040] The 3D structure of XOD was obtained from the PDB database (PDB ID: 3BDJ), and the C chain containing MoS was retained for docking studies. After removing the water molecules and adding polar hydrogen atoms, the all-atom Kollman combined diatomic local charge of XOD was assigned. The gridbox was set in the predicted XOD active pocket (containing the MoS hydrophobic cavity), and the grid was positioned as The grid spacing is
[0041] The results are as follows Figure 4 As shown, A is the conformation of Gly-Ile-Pro-Gly-Phe-Gly-Gly-Phe in the XOD pocket; B. Binding mode in the XOD active site; C. Interaction plane diagram. The benzene rings on multiple phenylalanines in the Gly-Ile-Pro-Gly-Phe-Gly-Gly-Phe polypeptide form π-π conjugation with Phe798 and Ser1080, form hydrophobic interactions with Leu873 and Val1011, and form hydrogen bonds with Arg880, Arg912, Gly1039, Gly1193, Gln1194 and Glu1261, so the binding is relatively tight, which can effectively prevent the entry of purine substrates and achieve the activity inhibition effect of xanthine oxidase.
[0042] Example 4
[0043] The QSPH-Ⅰ, QSPH-Ⅱ and QSPH-Ⅲ prepared in Example 1 were subjected to an in vitro XOD inhibition experiment: 100 μL PBS adjusted to neutrality, 25 μL polypeptide solution and 25 μL 5U / mL XOD were added to a 96-well plate in sequence, mixed by oscillation, incubated at 37°C for 10 min, 50 μL 1mM xanthine and 25 μL 1mM NBT were added in sequence, mixed by oscillation, incubated at 37°C in the dark for 30 min, and the absorbance at 560 nm was detected. The positive drug was allopurinol, and the zero adjustment group used PBS instead of the sample and xanthine; the complete reaction group used PBS instead of the sample; and the sample control group used PBS instead of xanthine oxidase.
[0044] XOD inhibition rate (%) = [1-(C3-C4) / (C2-C1)] × 100%;
[0045] In the formula: C1 is the zero adjustment group; C2 is the complete reaction group; C3 is the sample reaction group; C4 is the sample control group.
[0046] The results are as follows Figure 5 As shown, Gly-Ile-Pro-Gly-Phe-Gly-Gly-Phe polypeptide has a good inhibitory effect on xanthine oxidase.
[0047] The QSPH-Ⅰ prepared in Example 1 was subjected to a cytotoxicity experiment: LO2 cells in the logarithmic growth phase were taken to make a uniform single-cell suspension, counted and diluted to 20,000 / 100 μL with culture medium, and 100 μL was spread on a 96-well plate in each well. After culturing for 12-16 hours, the old culture medium was discarded, and culture medium containing polypeptides at different concentrations (culture medium: polypeptide solution = 99:1) was added to continue culturing for 24 hours. Finally, 100 μL of new culture medium and 15 μL of 0.5 mg / mL thiazolyl blue solution were added to each well under light-proof conditions, incubated in an incubator for 4 hours, and the supernatant was discarded. 150 μL of DMSO was added to each well and shaken in the dark for 10 minutes, and the absorbance was detected at 490 nm. Six parallel wells were set for each group of samples, and a PBS control group was set; the formula for calculating cell survival rate is as follows:
[0048] Cell survival rate (%) = [(A1-A0) / (A2-A0)] × 100%;
[0049] In the formula: A0 is the blank group; A1 is the sample group; A2 is the control group.
[0050] The results are as follows Figure 6 As shown, at a concentration of 0.1 to 10 μg / mL, the Gly-Ile-Pro-Gly-Phe-Gly-Gly-Phe polypeptide has a growth-promoting effect on LO2 cells, and the cell survival rate is between 98% and 120%.
[0051] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms should not be understood as necessarily being directed to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification.
[0052] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A polypeptide of Rana spinosa that inhibits xanthine oxidase activity, characterized in that: Its amino acid sequence is shown in SEQ ID NO:
1.
2. A method for preparing a Rana spinosa polypeptide that inhibits xanthine oxidase activity as claimed in claim 1, characterized in that: The following steps are involved: (1) Add distilled water to the frog skin of Rana spinosa at a material-liquid ratio of 1 g:15-25 mL and homogenize, adjust the pH to 6.5-7.5, add 4%-6% papain according to the weight of frog skin, adjust the enzymatic hydrolysis temperature to 40-50℃, and after enzymatic hydrolysis for 4-6 hours, inactivate the enzyme with boiling water for 10 minutes; (2) Adjust the pH of the enzymatic solution after the enzyme inactivation in step (1) to 1.0-3.0, add 4%-6% acid protease according to the weight of frog skin, adjust the enzymatic hydrolysis temperature to 45-55°C, and inactivate the enzyme in boiling water for 10 min after the enzymatic hydrolysis for 4-6 h; (3) Centrifuging the enzymatic hydrolysate after the enzyme inactivation in step (2), taking the supernatant, and subjecting it to ultrafiltration and chromatography, wherein the ultrafiltration uses an ultrafiltration tube with a molecular weight cutoff of 3 kD to collect enzymatic hydrolysate with a molecular weight less than 3 kD; and obtaining a Rana spinosa polypeptide that inhibits xanthine oxidase activity.
3. The preparation method according to claim 2, characterized in that: In step (1), the enzymatic activity of papain is ≥200 U / mg.
4. The preparation method according to claim 2, characterized in that: In step (2), the enzyme activity of the acidic protease is ≥ 200 U / mg.
5. The preparation method according to claim 2, characterized in that: In step (3), the chromatography is to use Sephadex G-15 gel chromatography column to perform column chromatography on the ultrafiltered enzymatic hydrolysate: the loading concentration is 20-40 mg / mL, the loading volume is 2-4 mL, the flow rate is 980 μL / min, one tube is collected every 10 minutes, and the absorbance curve is detected at 220 nm and plotted.
6. The preparation method according to claim 5, characterized in that: The components after chromatography were purified by reversed-phase HPLC. The conditions of reversed-phase HPLC were as follows: injection volume 10-20 μL; a C18 reversed-phase column was used, the column temperature was 25-30°C, the mobile phase was: A was water containing 0.1% trifluoroacetic acid, B was acetonitrile, gradient elution: 0-40 min, acetonitrile concentration from 0 to 50%, elution rate 1.0 mL / min; UV detection wavelength was 280 nm.
7. Use of the Rana spinosa polypeptide as claimed in claim 1 in the preparation of uric acid-lowering drugs.
Citation Information
Patent Citations
Inducing culture method for improving accumulation amounts of astaxanthin and algal oil in green algae cells
CN109439611A
Method for promoting growth of haematococcus pluvialis and accumulation of astaxanthin
CN110484451A
Cod polypeptide with xanthine oxidase inhibitory activity
CN113005166A
Xanthine oxidase inhibitory peptide and application thereof
CN113144169A
Small molecule peptide with xanthine oxidase inhibitory activity and application thereof
CN115385986A
